Millennium Management
NRIX icon

Millennium Management’s Nurix Therapeutics NRIX Stock Holding History

Millennium Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.47M Buy
546,297
+366,538
+204% +$6.08M ﹤0.01% 2340
2025
Q4 		$3.41M Sell
179,759
-1,344,200
-88% -$19.3M ﹤0.01% 3425
2025
Q3 		$14.1M Buy
1,523,959
+596,401
+64% +$6.19M 0.01% 2040
2025
Q2 		$10.6M Buy
927,558
+53,159
+6% +$574K 0.01% 2197
2025
Q1 		$10.4M Buy
874,399
+450,262
+106% +$7.53M 0.01% 2149
2024
Q4 		$7.99M Buy
424,137
+202,419
+91% +$4.64M ﹤0.01% 2389
2024
Q3 		$4.98M Sell
221,718
-377,905
-63% -$8.56M ﹤0.01% 2843
2024
Q2 		$12.5M Buy
599,623
+225,374
+60% +$3.51M 0.01% 1892
2024
Q1 		$5.5M Sell
374,249
-3,339
-0.9% -$35.9K ﹤0.01% 2766
2023
Q4 		$3.9M Buy
377,588
+89,431
+31% +$613K ﹤0.01% 3002
2023
Q3 		$2.26M Sell
288,157
-356,254
-55% -$3.25M ﹤0.01% 3440
2023
Q2 		$6.44M Buy
644,411
+182,819
+40% +$1.86M ﹤0.01% 2424
2023
Q1 		$4.1M Sell
461,592
-85,743
-16% -$894K ﹤0.01% 2781
2022
Q4 		$6.01M Sell
547,335
-192,590
-26% -$2.32M ﹤0.01% 2656
2022
Q3 		$9.64M Sell
739,925
-72,003
-9% -$1.14M 0.01% 2192
2022
Q2 		$10.3M Buy
811,928
+445,696
+122% +$5.05M 0.01% 2000
2022
Q1 		$5.13M Sell
366,232
-230,054
-39% -$4.08M ﹤0.01% 2912
2021
Q4 		$17.3M Buy
596,286
+359,403
+152% +$10.9M 0.01% 1582
2021
Q3 		$7.1M Sell
236,883
-189,103
-44% -$5.84M ﹤0.01% 2478
2021
Q2 		$11.3M Buy
425,986
+186,051
+78% +$5.46M 0.01% 1747
2021
Q1 		$7.46M Buy
239,935
+126,731
+112% +$4.79M 0.01% 2119
2020
Q4 		$3.72M Buy
+113,204
New +$3.75M ﹤0.01% 2727

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Millennium Management's NRIX Position: Q1 2026 in Review

Millennium Management increased its Nurix Therapeutics (NRIX) stake by 204% in Q1 2026, buying an estimated $6.08M and bringing the position to 546,297 shares worth $8.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Millennium Management first reported a position in NRIX in Q4 2020 and has held it in 22 quarters since. The position peaked at $17.3M in Q4 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Millennium Management held 546,297 shares of Nurix Therapeutics worth $8.47M as of Q1 2026.
  • Millennium Management bought 366,538 Nurix Therapeutics shares in Q1 2026, an estimated $6.08M.
  • Nurix Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2340 holding.
  • Millennium Management first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Millennium Management's Nurix Therapeutics position peaked at $17.3M in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.